Ticagrelor: the first novel reversible P2Y₁₂ inhibitor

Abstract

Introduction: Dual antiplatelet therapy is a standard of care for treating patients with acute coronary syndrome (ACS). Combination therapy with aspirin and one of the P2Y₁₂ inhibitors (clopidogrel, prasugrel, or most recently, ticagrelor) has been recommended by both ACC/AHA and ESC guidelines for ACS patients.

Areas covered: Ticagrelor is the first generation of a new class of reversible P2Y₁₂ inhibitors, recently added to updated ACC and ESC guidelines for use in patients with ACS. The authors review the studies that evaluate the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of ticagrelor in comparison to currently available antiplatelet agents.

Expert opinion: Ticagrelor 180 mg loading dose followed by 90 mg b.i.d. is significantly more efficacious and, in general, as safe as clopidogrel in the treatment of all patients with an ACS regardless of treatment strategy. In addition, besides aspirin compared to placebo, it is the only pharmaceutical intervention shown to have a cardiovascular mortality benefit within 1 year in a broad ACS population. Whether this surprising benefit is realized in other populations is currently being tested.

Keywords::

• acute coronary syndrome
• clopidogrel
• P2Y₁₂ antagonist
• ticagrelor

Notes